Develops small-molecule drug candidates for patients with muscular dystrophies and serious cardiac diseases.
10-K for FY2025, filed Feb 26, 2026At Edgewise, we appreciate the life-limiting impact of serious muscle diseases. Our science-driven culture places patients first as we…View ↗
10-Q for Q3 FY2026, filed Nov 4, 2026
$1.2BView ↗
8-K, filed Aug 6, 2026
In July 2026, Edgewise completed the previously announced transaction under which Servier, an independent international pharmaceutical…View ↗
Broader clinical pipeline
The older report described a lead clinical-stage candidate with other programs still preclinical; the latest describes multiple clinical-stage programs in muscular dystrophies and severe cardiac diseases, alongside preclinical programs.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 26, 2026Since our inception in 2017, our precision medicine muscle platform has generated several programs to address a variety of muscle…View ↗
At Edgewise, we appreciate the life-limiting impact of serious muscle diseases. Our science-driven culture places patients first as we…View ↗
Cardiometabolic focus
The older report framed the preclinical discovery program as aimed at other cardiac disorders; the latest describes it as exploring candidates for cardiometabolic diseases.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 26, 2026Our EDG-003 cardiovascular discovery program also has the potential to yield novel molecules that could become new therapeutic options for…View ↗
In addition, our EDG-003 discovery program is exploring candidates with unique properties to address cardiometabolic diseases. We believe…View ↗
Competes with Sarepta Therapeutics, Nippon Shinyaku, Solid Biosciences, Genethon, Dyne Therapeutics, Avidity Biosciences, REGENXBIO, Wave Life Sciences, Entrada Therapeutics, Vertex, PTC Therapeutics, Capricor Therapeutics, Satellos Bioscience, Bristol-Myers Squibb, Cytokinetics, Imbria Pharmaceuticals, Lexicon Pharmaceuticals, Celltrion, Braveheart Bio, and Pfizer
10-K for FY2025, filed Feb 26, 2026In addition, there are four exon skipping drugs which are marketed under an accelerated approval pathway from the FDA: EXONDYS 51…View ↗
Loading...